Is Neutropenia an Indicator of Leukemia?
Neutropenia alone is not a reliable indicator of leukemia, but it can be a presenting feature in certain high-risk contexts and warrants careful evaluation to exclude underlying malignancy.
Understanding the Relationship
Neutropenia and leukemia have a complex, bidirectional relationship that requires careful clinical interpretation:
When Neutropenia May Signal Leukemia
Isolated neutropenia can rarely be the sentinel presentation of acute myeloid leukemia (AML), particularly AML with myelodysplasia-related changes (AML-MRC). A recent case report demonstrates that persistent isolated neutropenia in an elderly patient progressed to AML-MRC with high-risk TP53 deletion within 6 months 1. This challenges the common "watch-and-wait" approach to isolated neutropenia in older adults.
In acute leukemia at diagnosis, neutropenia occurs in 35-48% of AML cases and 13-30% of acute lymphoblastic leukemia (ALL) cases during induction chemotherapy 2. However, this represents neutropenia as a consequence of the leukemia itself or its treatment, not as an isolated presenting sign.
Neutropenia as a Consequence, Not Cause
More commonly, neutropenia develops as a complication of leukemia treatment rather than being the initial indicator. Febrile neutropenia occurs regularly during chemotherapy-induced myelosuppression, with infection rates of 10-57% depending on the regimen 2. In children with AML, 87.3% experience at least one febrile neutropenia episode during induction therapy 3.
Congenital Neutropenia and Leukemia Risk
Severe congenital neutropenia (SCN) carries an inherent risk of malignant transformation to myelodysplastic syndromes (MDS) or AML, independent of treatment. The cumulative incidence reaches 22% after 15 years of G-CSF therapy, with risk increasing in the first 10 years and plateauing at 2-3% per year thereafter 4. This transformation can occur even without G-CSF therapy 5. Mutations in the ELA2 gene encoding neutrophil elastase account for most autosomal dominant SCN cases that demonstrate neoplastic progression 6.
The French Severe Chronic Neutropenia Registry found MDS/AL cumulative incidence of 2.7% at 10 years and 8.1% at 20 years, occurring exclusively in patients with severe congenital neutropenia and Shwachman-Diamond syndrome 7. Risk factors included diagnostic category, severity of neutropenia, younger age at diagnosis, and strong G-CSF exposure 7.
Critical Clinical Distinctions
Important caveats:
- Cyclic, idiopathic, and autoimmune neutropenia have virtually no risk of evolving to MDS or AML 5
- Neutropenia in cancer patients is more commonly due to chemotherapy-induced myelosuppression than the underlying malignancy itself 8, 9
- In febrile neutropenic patients, only 50-60% have an established or occult infection; approximately 10-20% with counts <100/µL develop bloodstream infections 10
Practical Approach to Evaluation
When encountering neutropenia, do not dismiss persistent isolated neutropenia in older adults as benign. The key distinguishing features requiring urgent evaluation include:
- Persistent unexplained neutropenia despite removal of potential causes (medications, nutritional deficiencies)
- Progressive decline in neutrophil counts over serial measurements
- Associated symptoms: easy bruising, splenomegaly, constitutional symptoms, or recurrent infections
- Other subtle cytopenias on careful review of complete blood counts
- Age >60 years with new-onset neutropenia
For persistent isolated neutropenia, particularly in elderly patients, bone marrow biopsy with cytogenetics and molecular studies should not be deferred 1. Waiting for additional cytopenias to develop may miss critical windows for early intervention in high-risk clonal evolution.
In contrast, brief neutropenia during active chemotherapy for known malignancy is expected and managed supportively with antimicrobials and G-CSF as indicated, rather than prompting concern for new leukemia 8, 11, 9.
Diagnostic Biomarkers
Elevated sTNF-R1 and IL-8 levels correlate with infection in neutropenic acute leukemia patients, with combined detection showing an AUC of 0.932 for diagnosing concurrent infections 12. However, these markers identify infectious complications rather than the underlying malignancy itself.
The bottom line: Neutropenia is not a specific indicator of leukemia in most cases, but persistent unexplained neutropenia—especially isolated neutropenia in older adults—demands thorough evaluation including bone marrow examination to exclude evolving myeloid malignancy. Clinical inertia in this setting can result in missed opportunities for early diagnosis of high-risk disease 1.